Italian biotech company Aptadir, which develops RNA inhibitor therapies for genetic diseases, has closed a €40 million seed round with investors including 4BIO Ventures and CDP Venture Capital.
Aptadir, an Italian biotech company active in the development of therapies based on RNA inhibitors for the treatment of genetic diseases that currently have no cure, has successfully completed a €40 million “seed” round. The capital increase was subscribed, among others, by 4BIO Ventures, CDP Venture Capital, XGEN Venture, Extend, Indaco Venture Partners, Deeptech Fund, Angelini Ventures and CE Ventures.
The company’s proprietary technology aims to counteract DNA methylation at the level of individual genes, reactivating gene expression and restoring normal biological function.
Aptadir was assisted by BonelliErede with a multidisciplinary team made up of Partner Giulia Bianchi Frangipane, Managing Associate Enrico Goitre, Associates Alessandro Cicala, Camilla Larcher and Francesca Gea Rusconi and Davide Cardinali. For labor law aspects, BonelliErede relied on a team made up of Partner Vittorio Pomarici, Senior Associate Alessia Varesi, Associate Claudia Numerati and Michele Fava. Golden power aspects were handled by Partner Massimo Merola.
4Bio Capital was assisted by Orrick with a team made up of Partner Attilio Mazzilli, Partner Livia Maria Pedroni, lawyer Pierpaolo Suma and trainee Carlo Alberto Barbieri. Golden power aspects were handled by Partner Mariangela Di Giandomenico and Associate Alessandro Amato.
CDP Venture Capital was assisted by the law firm Dentons in the investment made through the “Digital Transition Fund – PNRR” and “Technology Transfer” funds (the latter operating through Extend), with a multidisciplinary team led by Partner Antonio Legrottaglie and made up of Associate Elis Palazzi and trainee Giacomo Di Salvo, for corporate aspects, as well as by Partner Michele Carpagnano, supported by Counsel Giulia Giordano and trainee Claudio Bassetti, for FDI/Golden Power aspects. The transaction is part of the established relationship in which Dentons assists CDP Venture Capital in implementing its investment strategy.
CDP Venture Capital also followed the transaction with a team led by General Counsel Alessandro di Gioia, together with Matteo Fittante, Head of Legal Affairs for Investments through SPVs and PNRR.
XGEN Venture was assisted by A&O Shearman with a team made up of Partner Emanuele Trucco, supported by trainee Giorgia Lanzarotti for corporate aspects and by Senior Associate Arianna Fletcher with trainee Carolina Proietti for golden power aspects.
The notarial aspects of the transaction were entrusted to notary Federico Mottola Lucano of ZNR Notai, with the collaboration of Camilla Tolasi.
